Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aristaless-related homeobox protein (ARX) is a transcription factor encoded by the ARX gene on the X chromosome. It is a member of the homeobox gene family and contains conserved domains including a paired-like homeodomain and an aristaless domain. ARX is crucial for embryonic development, especially of the brain, pancreas, testes, and skeletal muscles. Its primary molecular function is as a DNA-binding transcriptional repressor, acting on genes involved in neuronal migration, differentiation, and proliferation. ARX binds to a core “TAAT” sequence within promoter regions and can act through protein-protein interactions involving Groucho and CtBP co-repressors[1][2][3][5]. Mutations in ARX, both point and polyalanine repeat expansions, are associated with a broad spectrum of neurodevelopmental disorders (X-linked intellectual disability, lissencephaly, infantile epileptic encephalopathy, Partington syndrome), often involving severe brain malformations, epilepsy, and endocrine defects[1][3][5]. ARX is thus considered a critical therapeutic and diagnostic target for congenital brain disorders, epilepsy, and intellectual disabilities.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aristaless-related homeobox protein (ARX).